The present disclosure provides an adjuvant that can boost the quantitative expansion of immune cells in vivo, and a combination comprising the adjuvant and immune cells. The present disclosure also provides a cascade booster system comprising the adjuvant and modified immune cells. The present disclosure also provides a treatment method using the adjuvant and the immune cells of the present disclosure.

The present application provides cord blood-derived natural killer (CB-NK) cells engineered to express chimeric receptors that target ADGRE2. Pharmaceutical compositions, kits and methods of treating cancer are also provided.

Provided are methods for disrupting Pdcd1, Adora2a, and Ctla4 genes using a Cas and guide RNAs targeting the three genes. Also provided are methods for treatment of cancers and/tumors by administering to subjects in need thereof engineered immune cells wherein the Pdcd1, Adora2a, and Ctla4 genes are disrupted in the engineered immune cells and wherein the engineered immune cells optionally further comprise a chimeric antigen receptor for targeting cancer or tumor cells.

Disclosed herein are engineered cells and/or hypoimmunogenic cells including engineered and/or hypoimmunogenic stem cells, engineered and/or hypoimmunogenic cells differentiated therefrom, engineered and/or hypoimmunogenic CAR-T cells (primary or differentiated from engineered and/or hypoimmunogenic stem cells) and related methods of their use and generation for use in the treatment of autoimmune diseases/disorders and/or inflammatory diseases/disorders. Provided herein are engineered and/or hypoimmunogenic cells exhibiting reduced expression of MHC class I and/or MHC class II human leukocyte antigens and T-cell receptors for use in the treatment of autoimmune diseases/disorders and/or inflammatory diseases/disorders. In some embodiments, such cells also exogenously express one or more tolerogenic factors such as CD47 and one or more chimeric antigen receptors (CARS).